Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Jiangdong Qiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9632-1850; OpenAlex author ID A5000993585. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. First author DOI 10.1038/s41392-026-02741-1↗
  2. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Co-author DOI 10.1016/j.canlet.2025.217751↗
  3. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Co-author DOI 10.1016/j.isci.2024.109406↗
  4. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Co-author DOI 10.1186/s12943-024-02050-7↗
  5. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. First author DOI 10.1093/bjs/znac375↗
  6. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
  7. Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients. First author DOI 10.3389/fsurg.2022.989065↗
  8. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Co-author DOI 10.1002/cac2.12204↗
  9. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  10. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  11. Targeting hypoxic tumor microenvironment in pancreatic cancer. Co-author DOI 10.1186/s13045-020-01030-w↗
  12. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.709669↗
  13. Arginine metabolism: a potential target in pancreatic cancer therapy. Co-author DOI 10.1097/cm9.0000000000001216↗
  14. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  15. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1103-2↗
  16. Low hENT1 expression indicates poor prognosis in gemcitabine-treated pancreatic cancer patients Co-author DOI 10.21203/rs.2.17850/v1↗
  17. NF-κB in pancreatic cancer: Its key role in chemoresistance. Co-author DOI 10.1016/j.canlet.2018.02.011↗
  18. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Co-author DOI 10.1186/s12943-017-0755-z↗
  19. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s13046-018-0947-4↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 17 shared papers, 2018–2026 · strength 2.36
  2. Yupei Zhao · 13 shared papers, 2018–2026 · strength 1.59
  3. Lei You · 13 shared papers, 2018–2025 · strength 1.53
  4. Zhe Cao · 10 shared papers, 2018–2026 · strength 1.27
  5. Gang Yang · 11 shared papers, 2018–2025 · strength 1.26
  6. Jinxin Tao · 7 shared papers, 2021–2025 · strength 1.16
  7. Fangyu Zhao · 9 shared papers, 2019–2023 · strength 1.07
  8. Yueze Liu · 8 shared papers, 2019–2024 · strength 1.01
  9. Guangyu Chen · 6 shared papers, 2021–2025 · strength 0.89
  10. Wenhao Luo · 5 shared papers, 2019–2026 · strength 0.86
  11. Mengyu Feng · 6 shared papers, 2018–2021 · strength 0.54
  12. Jinshou Yang · 4 shared papers, 2019–2021 · strength 0.49
  13. Guangbing Xiong · 4 shared papers, 2018–2023 · strength 0.45
  14. Ruobing Wang · 2 shared papers, 2024 · strength 0.39
  15. Bo Xu Ren · 2 shared papers, 2021–2025 · strength 0.37
  16. Jin Gu · 2 shared papers, 2021–2025 · strength 0.32
  17. Hao Chen · 1 shared paper, 2026 · strength 0.26
  18. Yuejuan Cheng · 1 shared paper, 2026 · strength 0.26
  19. Chunmei Bai · 1 shared paper, 2026 · strength 0.26
  20. Gang Yang · 2 shared papers, 2019–2023 · strength 0.25
  21. Jianchun Xiao · 2 shared papers, 2019–2021 · strength 0.21
  22. Hao Chen · 1 shared paper, 2025 · strength 0.21
  23. Xinqi Li · 1 shared paper, 2025 · strength 0.21
  24. Yu-Pei Zhao · 1 shared paper, 2025 · strength 0.21
  25. Yibo Fu · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.